Spots Global Cancer Trial Database for A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Official Title: A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease
Study ID: NCT00246090
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Birmingham Hematology and Oncology, Birmingham, Alabama, United States
Birmingham Hematology and Oncology, Birmingham, Alabama, United States
Mercy Cancer Center, Hot Springs, Arkansas, United States
Arkansas Cancer Research Center, Little Rock, Arkansas, United States
Wilshire Oncology Medical Group, Inc., La Verne, California, United States
Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States
Rocky Mountain Cancer Center-Rose, Denver, Colorado, United States
Rocky Mountain Cancer Center, Littleton, Colorado, United States
Cancer Research Network, Plantation, Florida, United States
Hematology-Oncology Associates, Port Saint-Lucie, Florida, United States
Dr. Elizabeth Tan-Chiu, PA, Tamarac, Florida, United States
Peachtree Hematology And Oncology Consultants, Atlanta, Georgia, United States
University of Chicago, Chicago, Illinois, United States
Decatur Memorial Hospital, Decatur, Illinois, United States
Cancer Care and Hematology Specialist of Chicagoland, Niles, Illinois, United States
Central Indiana Cancer Center, Indianapolis, Indiana, United States
Monroe Medical Center, Munster, Indiana, United States
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Frederick Memorial Hospital, Regional Cancer Therapy Center, Frederick, Maryland, United States
Park Nicollet Institute, Minneapolis, Minnesota, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Montana Cancer Specialists, Missoula, Montana, United States
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
New York Oncology Hematology, P.C, Albany, New York, United States
North Shore Hematology Oncology Associates, East Setakuet, New York, United States
Huntington Medical Group, PC, Huntington Station, New York, United States
Weill Cornell Breast Cancer Center, New York, New York, United States
SUNY Upstate Medical University, Syracuse, New York, United States
Northwestern Carolina Oncology And Hematology, PA, Hudson, North Carolina, United States
Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States
'Signal Point Hematology/Oncology, Inc., Middletown, Ohio, United States
Medical University of Ohio, Toledo, Ohio, United States
Cancer Care Associates, Oklahoma City, Oklahoma, United States
Cancer Care Associates, Oklahoma City, Oklahoma, United States
Cancer Care Associates, Tulsa, Oklahoma, United States
Willamette Valley Cancer Center, Eugene, Oregon, United States
Northwest Cancer Specialist Rose Qtr, Portland, Oregon, United States
Kaiser Permanente, Central Interstate Clinic, Hematology Oncology, Portland, Oregon, United States
Northwest Cancer Specialist Hoyt, Portland, Oregon, United States
Charleston Hematology Oncology, Charleston, South Carolina, United States
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Harrington Cancer Center, Amarillo, Texas, United States
Texas Oncology, P.A. Bedford, Bedford, Texas, United States
Center For Oncology Research and Treatment, PA, Dallas, Texas, United States
Texas Oncology PA, Dallas, Texas, United States
Sammons Cancer Center-Dallas, Dallas, Texas, United States
El Paso Cancer Treatment Center West, El Paso, Texas, United States
El Paso Cancer Treatment Center, El Paso, Texas, United States
Texas Oncology PA, Houston, Texas, United States
Baylor College of Medicine, Breast Cancer Clinic, Houston, Texas, United States
North Texas Regional Cancer Center, Plano, Texas, United States
Tyler Cancer Center, Tyler, Texas, United States
Valley Oncology PA, Weslaco, Texas, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
Fairfax Northern VA Hematology Oncology PC, Fairfax, Virginia, United States
Oncology and Hematology Associates, Salem, Virginia, United States
Cancer Care Northwest, Spokane, Washington, United States
Northwest Cancer Specialist, Vancouver, Washington, United States
Yakima Valley Memorial Hospital, Yakima, Washington, United States
Hamilton Health Sciences Juravinski Cancer Centre, Hamilton, Ontario, Canada
NW Ontario Regional Cancer Centre, Thunder Bay, Ontario, Canada
Toronto East General Hospital, Toronto, Ontario, Canada
Centre Hospitaliere Universitaire de Montreal, Montreal, Quebec, Canada
McGill University, Dept. of Oncology, Clinical Research Program, Montreal, Quebec, Canada
Contact Details
Name: Dale Shuster, Ph.D.
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
